Bristol Myers Squibb's Second Largest Investor Trims Stake

Independent Franchise Partners LLP reduces its holdings in the pharmaceutical company by 1.7%

Mar. 14, 2026 at 8:37am

Got story updates? Submit your updates here. ›

Independent Franchise Partners LLP, a major institutional investor, has trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 1.7% in the third quarter, according to a recent SEC filing. The firm still owns over 20 million shares of the biopharmaceutical company, making it Bristol Myers Squibb's second largest shareholder with a 6.1% stake worth $930 million.

Why it matters

Bristol Myers Squibb is a leading pharmaceutical company with a focus on oncology, hematology, immunology, and other specialty areas. Institutional investors like Independent Franchise Partners closely monitor and adjust their positions in major healthcare stocks like BMY, providing insights into market sentiment and potential shifts in the company's outlook.

The details

According to the 13F filing, Independent Franchise Partners sold 353,603 shares of Bristol Myers Squibb in the third quarter, reducing its total position to 20,623,351 shares. This stake represents approximately 1.01% of the company's outstanding shares. Bristol Myers Squibb remains Independent Franchise Partners' second largest holding, behind only Microsoft Corporation.

  • Independent Franchise Partners filed the 13F report covering the third quarter of 2026.

The players

Independent Franchise Partners LLP

An investment management firm that owns a major stake in Bristol Myers Squibb.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Independent Franchise Partners' Bristol Myers Squibb position, while relatively small, could signal a shift in sentiment around the pharmaceutical company's outlook. Investors will likely continue to monitor institutional ownership and trading activity in BMY stock for clues about the company's future performance.